Liposomal formulation of retinoids designed for enzyme triggered release

J Med Chem. 2010 May 13;53(9):3782-92. doi: 10.1021/jm100190c.


The design of retinoid phospholipid prodrugs is described based on molecular dynamics simulations and cytotoxicity studies of synthetic retinoid esters. The prodrugs are degradable by secretory phospholipase A(2) IIA and have potential in liposomal drug delivery targeting tumors. We have synthesized four different retinoid phospholipid prodrugs and shown that they form particles in the liposome size region with average diameters of 94-118 nm. Upon subjection to phospholipase A(2), the lipid prodrugs were hydrolyzed, releasing cytotoxic retinoids and lysolipids. The formulated lipid prodrugs displayed IC(50) values in the range of 3-19 microM toward HT-29 and Colo205 colon cancer cells in the presence of phospholipase A(2), while no significant cell death was observed in the absence of the enzyme.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Death
  • Cell Line, Tumor
  • Cytotoxins
  • Drug Design*
  • Humans
  • Inhibitory Concentration 50
  • Liposomes / chemistry*
  • Liposomes / therapeutic use
  • Molecular Dynamics Simulation
  • Nanoparticles
  • Particle Size
  • Phospholipases A2 / metabolism*
  • Phospholipids
  • Prodrugs / metabolism*
  • Retinoids / chemistry*
  • Retinoids / therapeutic use


  • Cytotoxins
  • Liposomes
  • Phospholipids
  • Prodrugs
  • Retinoids
  • Phospholipases A2